Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay.

Shi L, Westwood S, Baird AL, Winchester L, Dobricic V, Kilpert F, Hong S, Franke A, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Buckley NJ, Kate MT, Scheltens P, Vandenberghe R, Gabel S, Meersmans K, Engelborghs S, De Roeck EE, Sleegers K, Frisoni GB, Blin O, Richardson JC, Bordet R, Molinuevo JL, Rami L, Wallin A, Kettunen P, Tsolaki M, Verhey F, Lleó A, Alcolea D, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Johannsen P, Teunissen CE, Freund-Levi Y, Frölich L, Legido-Quigley C, Barkhof F, Blennow K, Zetterberg H, Baker S, Morgan BP, Streffer J, Visser PJ, Bertram L, Lovestone S, Nevado-Holgado AJ.

Alzheimers Dement. 2019 Sep 5. pii: S1552-5260(19)35118-0. doi: 10.1016/j.jalz.2019.06.4951. [Epub ahead of print]

2.

Hippocampal atrophy has limited usefulness as a diagnostic biomarker on the early onset Alzheimer's disease patients: A comparison between visual and quantitative assessment.

Falgàs N, Sánchez-Valle R, Bargalló N, Balasa M, Fernández-Villullas G, Bosch B, Olives J, Tort-Merino A, Antonell A, Muñoz-García C, León M, Grau O, Castellví M, Coll-Padrós N, Rami L, Redolfi A, Lladó A.

Neuroimage Clin. 2019;23:101927. doi: 10.1016/j.nicl.2019.101927. Epub 2019 Jul 5.

3.

The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk.

Deming Y, Filipello F, Cignarella F, Cantoni C, Hsu S, Mikesell R, Li Z, Del-Aguila JL, Dube U, Farias FG, Bradley J, Budde J, Ibanez L, Fernandez MV, Blennow K, Zetterberg H, Heslegrave A, Johansson PM, Svensson J, Nellgård B, Lleo A, Alcolea D, Clarimon J, Rami L, Molinuevo JL, Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, Ewers M, Harari O, Haass C, Brett TJ, Benitez BA, Karch CM, Piccio L, Cruchaga C.

Sci Transl Med. 2019 Aug 14;11(505). pii: eaau2291. doi: 10.1126/scitranslmed.aau2291.

PMID:
31413141
4.

Tau Protein is Associated with Longitudinal Memory Decline in Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels.

Tort-Merino A, Olives J, León M, Peñaloza C, Valech N, Santos-Santos MA, Càmara E, Grönholm-Nyman P, Martínez-Lage P, Fortea J, Molinuevo JL, Sánchez-Valle R, Laine M, Rodríguez-Fornells A, Rami L.

J Alzheimers Dis. 2019;70(1):211-225. doi: 10.3233/JAD-190046.

PMID:
31177219
5.

Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort.

Kim M, Snowden S, Suvitaival T, Ali A, Merkler DJ, Ahmad T, Westwood S, Baird A, Proitsi P, Nevado-Holgado A, Hye A, Bos I, Vos S, Vandenberghe R, Teunissen C, Ten Kate M, Scheltens P, Gabel S, Meersmans K, Blin O, Richardson J, De Roeck E, Sleegers K, Bordet R, Rami L, Kettunen P, Tsolaki M, Verhey F, Sala I, Lléo A, Peyratout G, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Engelborghs S, Frisoni GB, Molinuevo JL, Wallin A, Popp J, Martinez-Lage P, Bertram L, Barkhof F, Ashton N, Blennow K, Zetterberg H, Streffer J, Visser PJ, Lovestone S, Legido-Quigley C.

Alzheimers Dement. 2019 Jun;15(6):817-827. doi: 10.1016/j.jalz.2019.03.004. Epub 2019 May 8.

6.

Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project.

van Maurik IS, Slot RER, Verfaillie SCJ, Zwan MD, Bouwman FH, Prins ND, Teunissen CE, Scheltens P, Barkhof F, Wattjes MP, Molinuevo JL, Rami L, Wolfsgruber S, Peters O, Jessen F, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2019 Apr 16;11(1):33. doi: 10.1186/s13195-019-0487-y.

7.

CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals.

Falcon C, Monté-Rubio GC, Grau-Rivera O, Suárez-Calvet M, Sánchez-Valle R, Rami L, Bosch B, Haass C, Gispert JD, Molinuevo JL.

Neuroimage Clin. 2019;23:101801. doi: 10.1016/j.nicl.2019.101801. Epub 2019 Apr 1.

8.

Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease.

Skouras S, Falcon C, Tucholka A, Rami L, Sanchez-Valle R, Lladó A, Gispert JD, Molinuevo JL.

Neuroimage Clin. 2019;22:101777. doi: 10.1016/j.nicl.2019.101777. Epub 2019 Mar 12.

9.

Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples.

Wolfsgruber S, Molinuevo JL, Wagner M, Teunissen CE, Rami L, Coll-Padrós N, Bouwman FH, Slot RER, Wesselman LMP, Peters O, Luther K, Buerger K, Priller J, Laske C, Teipel S, Spottke A, Heneka MT, Düzel E, Drzezga A, Wiltfang J, Sikkes SAM, van der Flier WM, Jessen F; Euro-SCD working group.

Alzheimers Res Ther. 2019 Jan 17;11(1):8. doi: 10.1186/s13195-018-0463-y.

10.

Computer-assisted prediction of clinical progression in the earliest stages of AD.

Rhodius-Meester HFM, Liedes H, Koikkalainen J, Wolfsgruber S, Coll-Padros N, Kornhuber J, Peters O, Jessen F, Kleineidam L, Molinuevo JL, Rami L, Teunissen CE, Barkhof F, Sikkes SAM, Wesselman LMP, Slot RER, Verfaillie SCJ, Scheltens P, Tijms BM, Lötjönen J, van der Flier WM.

Alzheimers Dement (Amst). 2018 Oct 8;10:726-736. doi: 10.1016/j.dadm.2018.09.001. eCollection 2018.

11.

Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.

Lleó A, Núñez-Llaves R, Alcolea D, Chiva C, Balateu-Paños D, Colom-Cadena M, Gomez-Giro G, Muñoz L, Querol-Vilaseca M, Pegueroles J, Rami L, Lladó A, Molinuevo JL, Tainta M, Clarimón J, Spires-Jones T, Blesa R, Fortea J, Martínez-Lage P, Sánchez-Valle R, Sabidó E, Bayés À, Belbin O.

Mol Cell Proteomics. 2019 Mar;18(3):546-560. doi: 10.1074/mcp.RA118.001290. Epub 2019 Jan 3.

PMID:
30606734
12.

Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease-Data from three memory clinic studies.

Hu X, Teunissen CE, Spottke A, Heneka MT, Düzel E, Peters O, Li S, Priller J, Buerger K, Teipel S, Laske C, Verfaillie SCJ, Barkhof F, Coll-Padrós N, Rami L, Molinuevo JL, van der Flier WM, Jessen F.

Alzheimers Dement. 2019 Feb;15(2):185-193. doi: 10.1016/j.jalz.2018.09.002. Epub 2018 Oct 12.

PMID:
30321506
13.

Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.

Falcon C, Tucholka A, Monté-Rubio GC, Cacciaglia R, Operto G, Rami L, Gispert JD, Molinuevo JL; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2018 Apr 16;19:190-201. doi: 10.1016/j.nicl.2018.04.016. eCollection 2018.

14.

Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data.

Bos I, Vos SJB, Jansen WJ, Vandenberghe R, Gabel S, Estanga A, Ecay-Torres M, Tomassen J, den Braber A, Lleó A, Sala I, Wallin A, Kettunen P, Molinuevo JL, Rami L, Chetelat G, de la Sayette V, Tsolaki M, Freund-Levi Y, Johannsen P; Alzheimer's Disease Neuroimaging Initiative, Novak GP, Ramakers I, Verhey FR, Visser PJ.

Front Aging Neurosci. 2018 Jun 25;10:193. doi: 10.3389/fnagi.2018.00193. eCollection 2018.

15.

Wishes and preferences for an online lifestyle program for brain health-A mixed methods study.

Wesselman LMP, Schild AK, Coll-Padros N, van der Borg WE, Meurs JHP, Hooghiemstra AM, Slot RER, Sannemann L, Rami L, Molinuevo JL, Bouwman FH, Jessen F, van der Flier WM, Sikkes SAM; Euro-SCD working group.

Alzheimers Dement (N Y). 2018 Apr 9;4:141-149. doi: 10.1016/j.trci.2018.03.003. eCollection 2018.

16.

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Mattsson N, Groot C, Jansen WJ, Landau SM, Villemagne VL, Engelborghs S, Mintun MM, Lleo A, Molinuevo JL, Jagust WJ, Frisoni GB, Ivanoiu A, Chételat G, Resende de Oliveira C, Rodrigue KM, Kornhuber J, Wallin A, Klimkowicz-Mrowiec A, Kandimalla R, Popp J, Aalten PP, Aarsland D, Alcolea D, Almdahl IS, Baldeiras I, van Buchem MA, Cavedo E, Chen K, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gill KD, Gkatzima O, Grimmer T, Hampel H, Herukka SK, Johannsen P, van Laere K, de Leon MJ, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Mroczko B, Nordlund A, Prabhakar S, Peters O, Rami L, Rodríguez-Rodríguez E, Roe CM, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Verhey FRJ, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Vandenberghe R, Brooks DJ, Fladby T, Rowe CC, Drzezga A, Verbeek MM, Sarazin M, Wolk DA, Fleisher AS, Klunk WE, Na DL, Sánchez-Juan P, Lee DY, Nordberg A, Tsolaki M, Camus V, Rinne JO, Fagan AM, Zetterberg H, Blennow K, Rabinovici GD, Hansson O, van Berckel BNM, van der Flier WM, Scheltens P, Visser PJ, Ossenkoppele R.

Alzheimers Dement. 2018 Jul;14(7):913-924. doi: 10.1016/j.jalz.2018.02.009. Epub 2018 Mar 28.

PMID:
29601787
17.

The Rationale Behind the New Alzheimer's Disease Conceptualization: Lessons Learned During the Last Decades.

Molinuevo JL, Minguillon C, Rami L, Gispert JD.

J Alzheimers Dis. 2018;62(3):1067-1077. doi: 10.3233/JAD-170698. Review.

18.

Structural Connectivity Alterations Along the Alzheimer's Disease Continuum: Reproducibility Across Two Independent Samples and Correlation with Cerebrospinal Fluid Amyloid-β and Tau.

Tucholka A, Grau-Rivera O, Falcon C, Rami L, Sánchez-Valle R, Lladó A, Gispert JD, Molinuevo JL; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2018;61(4):1575-1587. doi: 10.3233/JAD-170553.

19.

Executive and Language Subjective Cognitive Decline Complaints Discriminate Preclinical Alzheimer's Disease from Normal Aging.

Valech N, Tort-Merino A, Coll-Padrós N, Olives J, León M, Rami L, Molinuevo JL.

J Alzheimers Dis. 2018;61(2):689-703. doi: 10.3233/JAD-170627.

PMID:
29254090
20.

Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia.

Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, van der Flier WM, Villemagne VL, Frisoni GB, Fleisher AS, Lleó A, Mintun MA, Wallin A, Engelborghs S, Na DL, Chételat G, Molinuevo JL, Landau SM, Mattsson N, Kornhuber J, Sabri O, Rowe CC, Parnetti L, Popp J, Fladby T, Jagust WJ, Aalten P, Lee DY, Vandenberghe R, Resende de Oliveira C, Kapaki E, Froelich L, Ivanoiu A, Gabryelewicz T, Verbeek MM, Sanchez-Juan P, Hildebrandt H, Camus V, Zboch M, Brooks DJ, Drzezga A, Rinne JO, Newberg A, de Mendonça A, Sarazin M, Rabinovici GD, Madsen K, Kramberger MG, Nordberg A, Mok V, Mroczko B, Wolk DA, Meyer PT, Tsolaki M, Scheltens P, Verhey FRJ, Visser PJ; Amyloid Biomarker Study Group, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BNM, Blennow K, van Buchem MA, Cavedo E, Chen K, Chipi E, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gkatzima O, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Johannsen P, Klimkowicz-Mrowiec A, Köhler S, Koglin N, van Laere K, de Leon M, Lisetti V, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Nordlund A, Novak GP, Paraskevas GP, Perera G, Peters O, Ramakers IHGB, Rami L, Rodríguez-Rodríguez E, Roe CM, Rot U, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Zetterberg H.

JAMA Psychiatry. 2018 Jan 1;75(1):84-95. doi: 10.1001/jamapsychiatry.2017.3391. Erratum in: JAMA Psychiatry. 2018 Mar 1;75(3):303.

21.

Early Detection of Learning Difficulties when Confronted with Novel Information in Preclinical Alzheimer's Disease Stage 1.

Tort-Merino A, Valech N, Peñaloza C, Grönholm-Nyman P, León M, Olives J, Estanga A, Ecay-Torres M, Fortea J, Martínez-Lage P, Molinuevo JL, Laine M, Rodríguez-Fornells A, Rami L.

J Alzheimers Dis. 2017;58(3):855-870. doi: 10.3233/JAD-161173.

PMID:
28505969
22.

The APOE ε4 genotype modulates CSF YKL-40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2.

Gispert JD, Monté GC, Suárez-Calvet M, Falcon C, Tucholka A, Rojas S, Rami L, Sánchez-Valle R, Lladó A, Kleinberger G, Haass C, Molinuevo JL.

Alzheimers Dement (Amst). 2016 Dec 22;6:50-59. doi: 10.1016/j.dadm.2016.12.002. eCollection 2017.

23.

Implementation of subjective cognitive decline criteria in research studies.

Molinuevo JL, Rabin LA, Amariglio R, Buckley R, Dubois B, Ellis KA, Ewers M, Hampel H, Klöppel S, Rami L, Reisberg B, Saykin AJ, Sikkes S, Smart CM, Snitz BE, Sperling R, van der Flier WM, Wagner M, Jessen F; Subjective Cognitive Decline Initiative (SCD-I) Working Group.

Alzheimers Dement. 2017 Mar;13(3):296-311. doi: 10.1016/j.jalz.2016.09.012. Epub 2016 Nov 5.

24.

Altered Blood Gene Expression of Tumor-Related Genes (PRKCB, BECN1, and CDKN2A) in Alzheimer's Disease.

Antonell A, Lladó A, Sánchez-Valle R, Sanfeliu C, Casserras T, Rami L, Muñoz-García C, Dangla-Valls A, Balasa M, Boya P, Kalko SG, Molinuevo JL.

Mol Neurobiol. 2016 Nov;53(9):5902-5911. doi: 10.1007/s12035-015-9483-9. Epub 2015 Oct 28.

25.

CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study.

Dangla-Valls A, Molinuevo JL, Altirriba J, Sánchez-Valle R, Alcolea D, Fortea J, Rami L, Balasa M, Muñoz-García C, Ezquerra M, Fernández-Santiago R, Lleó A, Lladó A, Antonell A.

Mol Neurobiol. 2017 Nov;54(9):6647-6654. doi: 10.1007/s12035-016-0106-x. Epub 2016 Oct 13.

PMID:
27738874
26.

Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease.

Gispert JD, Suárez-Calvet M, Monté GC, Tucholka A, Falcon C, Rojas S, Rami L, Sánchez-Valle R, Lladó A, Kleinberger G, Haass C, Molinuevo JL.

Alzheimers Dement. 2016 Dec;12(12):1259-1272. doi: 10.1016/j.jalz.2016.06.005. Epub 2016 Jul 14.

PMID:
27423963
27.

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.

Suárez-Calvet M, Kleinberger G, Araque Caballero MÁ, Brendel M, Rominger A, Alcolea D, Fortea J, Lleó A, Blesa R, Gispert JD, Sánchez-Valle R, Antonell A, Rami L, Molinuevo JL, Brosseron F, Traschütz A, Heneka MT, Struyfs H, Engelborghs S, Sleegers K, Van Broeckhoven C, Zetterberg H, Nellgård B, Blennow K, Crispin A, Ewers M, Haass C.

EMBO Mol Med. 2016 May 2;8(5):466-76. doi: 10.15252/emmm.201506123. Print 2016 May.

28.

CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD.

Gispert JD, Monté GC, Falcon C, Tucholka A, Rojas S, Sánchez-Valle R, Antonell A, Lladó A, Rami L, Molinuevo JL.

Neurobiol Aging. 2016 Feb;38:47-55. doi: 10.1016/j.neurobiolaging.2015.10.022. Epub 2015 Nov 2.

PMID:
26827642
29.

Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.

Sierra-Rio A, Balasa M, Olives J, Antonell A, Iranzo A, Castellví M, Bosch B, Grau-Rivera O, Fernandez-Villullas G, Rami L, Lladó A, Sánchez-Valle R, Molinuevo JL.

Neurodegener Dis. 2016;16(1-2):69-76. doi: 10.1159/000439258. Epub 2015 Nov 12.

PMID:
26560503
30.

Informants' Perception of Subjective Cognitive Decline Helps to Discriminate Preclinical Alzheimer's Disease from Normal Aging.

Valech N, Mollica MA, Olives J, Tort A, Fortea J, Lleo A, Belén SS, Molinuevo JL, Rami L.

J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S87-98. doi: 10.3233/JAD-150117.

PMID:
26445275
31.

Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.

Lista S, Molinuevo JL, Cavedo E, Rami L, Amouyel P, Teipel SJ, Garaci F, Toschi N, Habert MO, Blennow K, Zetterberg H, O'Bryant SE, Johnson L, Galluzzi S, Bokde AL, Broich K, Herholz K, Bakardjian H, Dubois B, Jessen F, Carrillo MC, Aisen PS, Hampel H.

J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S171-91. doi: 10.3233/JAD-150202. Review.

PMID:
26402088
32.

Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies.

Rabin LA, Smart CM, Crane PK, Amariglio RE, Berman LM, Boada M, Buckley RF, Chételat G, Dubois B, Ellis KA, Gifford KA, Jefferson AL, Jessen F, Katz MJ, Lipton RB, Luck T, Maruff P, Mielke MM, Molinuevo JL, Naeem F, Perrotin A, Petersen RC, Rami L, Reisberg B, Rentz DM, Riedel-Heller SG, Risacher SL, Rodriguez O, Sachdev PS, Saykin AJ, Slavin MJ, Snitz BE, Sperling RA, Tandetnik C, van der Flier WM, Wagner M, Wolfsgruber S, Sikkes SA.

J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S63-86. doi: 10.3233/JAD-150154.

33.

Nonlinear cerebral atrophy patterns across the Alzheimer's disease continuum: impact of APOE4 genotype.

Gispert JD, Rami L, Sánchez-Benavides G, Falcon C, Tucholka A, Rojas S, Molinuevo JL.

Neurobiol Aging. 2015 Oct;36(10):2687-701. doi: 10.1016/j.neurobiolaging.2015.06.027. Epub 2015 Jul 8.

PMID:
26239178
34.

Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.

Toledo JB, Zetterberg H, van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L, Rami L, Hansson O, Sperling R, Engelborghs S, Osorio RS, Vanderstichele H, Vandijck M, Hampel H, Teipl S, Moghekar A, Albert M, Hu WT, Monge Argilés JA, Gorostidi A, Teunissen CE, De Deyn PP, Hyman BT, Molinuevo JL, Frisoni GB, Linazasoro G, de Leon MJ, van der Flier WM, Scheltens P, Blennow K, Shaw LM, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2015 Sep;138(Pt 9):2701-15. doi: 10.1093/brain/awv199. Epub 2015 Jul 27.

35.

Subtle visuomotor difficulties in preclinical Alzheimer's disease.

Mollica MA, Navarra J, Fernández-Prieto I, Olives J, Tort A, Valech N, Coll-Padrós N, Molinuevo JL, Rami L.

J Neuropsychol. 2017 Mar;11(1):56-73. doi: 10.1111/jnp.12079. Epub 2015 Jul 14.

PMID:
26172318
36.

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ; Amyloid Biomarker Study Group, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BN, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, Förster S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, Gómez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, Köhler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lleó A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendonça A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, Møllergård HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IH, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodríguez-Rodríguez E, Roe CM, Rot U, Rowe CC, Rüther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schröder J, Schütte C, Seo SW, Soetewey F, Soininen H, Spiru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJ, van Waalwijk van Doorn LJ, Waldemar G, Wallin A, Wallin ÅK, Wiltfang J, Wolk DA, Zboch M, Zetterberg H.

JAMA. 2015 May 19;313(19):1924-38. doi: 10.1001/jama.2015.4668.

37.

Initial phase of adaptation of Memory Alteration Test (M@T) in a Portuguese sample.

Sousa M, Pereira A, Costa R, Rami L.

Arch Gerontol Geriatr. 2015 Jul-Aug;61(1):103-8. doi: 10.1016/j.archger.2015.03.008. Epub 2015 Apr 6.

PMID:
25912751
38.

An approach to establish the uncertainty budget of catalytic activity concentration measurements in a reference laboratory.

Rami L, Canalias F.

Clin Chem Lab Med. 2015 Apr;53(5):743-51. doi: 10.1515/cclm-2014-0579.

PMID:
25283140
39.

Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease.

Rosén C, Andersson CH, Andreasson U, Molinuevo JL, Bjerke M, Rami L, Lladó A, Blennow K, Zetterberg H.

Dement Geriatr Cogn Dis Extra. 2014 Jul 31;4(2):297-304. doi: 10.1159/000362164. eCollection 2014 May.

40.

Bioresorption mechanisms of chitosan physical hydrogels: a scanning electron microscopy study.

Malaise S, Rami L, Montembault A, Alcouffe P, Burdin B, Bordenave L, Delmond S, David L.

Mater Sci Eng C Mater Biol Appl. 2014 Sep;42:374-84. doi: 10.1016/j.msec.2014.04.060. Epub 2014 May 5.

PMID:
25063131
41.

Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease.

Antonell A, Mansilla A, Rami L, Lladó A, Iranzo A, Olives J, Balasa M, Sánchez-Valle R, Molinuevo JL.

J Alzheimers Dis. 2014;42(3):901-8. doi: 10.3233/JAD-140624.

PMID:
25024322
42.

White matter changes in preclinical Alzheimer's disease: a magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid β protein 42 levels.

Molinuevo JL, Ripolles P, Simó M, Lladó A, Olives J, Balasa M, Antonell A, Rodriguez-Fornells A, Rami L.

Neurobiol Aging. 2014 Dec;35(12):2671-2680. doi: 10.1016/j.neurobiolaging.2014.05.027. Epub 2014 Jun 6.

PMID:
25002037
43.

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease.

Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, Glodzik L, van Harten AC, de Leon MJ, McHugh P, Mielke MM, Molinuevo JL, Mosconi L, Osorio RS, Perrotin A, Petersen RC, Rabin LA, Rami L, Reisberg B, Rentz DM, Sachdev PS, de la Sayette V, Saykin AJ, Scheltens P, Shulman MB, Slavin MJ, Sperling RA, Stewart R, Uspenskaya O, Vellas B, Visser PJ, Wagner M; Subjective Cognitive Decline Initiative (SCD-I) Working Group.

Alzheimers Dement. 2014 Nov;10(6):844-52. doi: 10.1016/j.jalz.2014.01.001. Epub 2014 May 3. Review.

44.

The Subjective Cognitive Decline Questionnaire (SCD-Q): a validation study.

Rami L, Mollica MA, García-Sanchez C, Saldaña J, Sanchez B, Sala I, Valls-Pedret C, Castellví M, Olives J, Molinuevo JL.

J Alzheimers Dis. 2014;41(2):453-66. doi: 10.3233/JAD-132027.

PMID:
24625794
45.

Usefulness of biomarkers in the diagnosis and prognosis of early-onset cognitive impairment.

Balasa M, Sánchez-Valle R, Antonell A, Bosch B, Olives J, Rami L, Castellví M, Molinuevo JL, Lladó A.

J Alzheimers Dis. 2014;40(4):919-27. doi: 10.3233/JAD-132195.

PMID:
24577466
46.

Physicochemical modulation of chitosan-based hydrogels induces different biological responses: interest for tissue engineering.

Rami L, Malaise S, Delmond S, Fricain JC, Siadous R, Schlaubitz S, Laurichesse E, Amédée J, Montembault A, David L, Bordenave L.

J Biomed Mater Res A. 2014 Oct;102(10):3666-76. doi: 10.1002/jbm.a.35035. Epub 2013 Nov 30.

PMID:
24293114
47.

IQ domain GTPase-activating protein 1 is involved in shear stress-induced progenitor-derived endothelial cell alignment.

Rami L, Auguste P, Thebaud NB, Bareille R, Daculsi R, Ripoche J, Bordenave L.

PLoS One. 2013 Nov 22;8(11):e79919. doi: 10.1371/journal.pone.0079919. eCollection 2013.

48.

Insights into the osteoblast precursor differentiation towards mature osteoblasts induced by continuous BMP-2 signaling.

Zouani OF, Rami L, Lei Y, Durrieu MC.

Biol Open. 2013 Jul 3;2(9):872-81. doi: 10.1242/bio.20134986. eCollection 2013.

49.

Decreased striatal dopamine transporter uptake in the non-fluent/agrammatic variant of primary progressive aphasia.

Gil-Navarro S, Lomeña F, Cot A, Lladó A, Montagut N, Castellví M, Bosch B, Rami L, Antonell A, Balasa M, Pavia J, Iranzo A, Molinuevo JL, Sánchez-Valle R.

Eur J Neurol. 2013 Nov;20(11):1459-e126. doi: 10.1111/ene.12196. Epub 2013 May 17.

PMID:
23679075
50.

Applying the IWG research criteria in clinical practice: feasibility and ethical issues.

Molinuevo JL, Rami L.

Med Clin North Am. 2013 May;97(3):477-84. doi: 10.1016/j.mcna.2012.12.018. Epub 2013 Feb 1. Review.

PMID:
23642582

Supplemental Content

Support Center